Emeryville-based Dynavax Technologies Corporation announced that the European Commission (EC) had granted Marketing Authorization for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine Approval based on safety and immunogenicity results from three Phase 3 clinical trials Statistically significantly higher and faster rates of protection and similar safety compared to Engerix-B in all 3 trials HEPLISAV B is the only 2-dose adult hepatitis B vaccine offering protection in just 1 month
EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that the European Commission (EC) has granted Marketing Authorization for HEPLISAV B (Hepatitis B Vaccine (Recombinant), Adjuvanted) for the active immunization against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The approval was issued following the European Medicines Agency (EMA)
| UPDATED: 19:03, Fri, Feb 19, 2021
Link copied
Brexit: EU can no longer fund bailout schemes says expert Sign up to receive our rundown of the day s top stories direct to your inbox
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters.
Sometimes they ll include recommendations for other related newsletters or services we offer.
Our Privacy Notice explains more about how we use your data, and your rights.
You can unsubscribe at any time.
The UK was pressured into signing up to the European Economic Community (EEC) by the US, a wrongheaded move that resulted in the complications of the Brexit vote, Express.co.uk was told. It comes as Britain approaches nearly three months since exiting the EU s single market and customs union. Tensions soared earlier this year after the EU, under European Commission President Ursula von der Leyen, led a charge against the UK s coronavirus vaccine supplies after the bloc was for
/PRNewswire/ Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today.
Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.